Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

East Hills, New York Clinical Trials

A listing of East Hills, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (183) clinical trials

RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease

To evaluate the effect of treatment with rifalazil versus placebo taken once weekly for 12 weeks on carotid atherosclerotic disease progression in patients who test positive for Chlamydia pneumoniae. Measurements of the carotid artery wall (intima-media thickness) and plaque characteristics will be evaluated with high-resolution magnetic resonance imaging (MRI) and ...

Phase

1.13 miles

Learn More »

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

The hypothesis is that the addition of daratumumab administered SC to standard MM regimens will improve responses compared to response data observed in completed phase 3 studies without daratumumab. Disease evaluations will include measurements of myeloma proteins, bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum ...

Phase

1.3 miles

Learn More »

Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss

Congenital cytomegalovirus (CMV) infection is the most frequent known viral cause of mental retardation, and is the leading non-genetic cause of sensorineural hearing loss in many countries including the United States. This is a Phase II international, multi-center, double-blind, placebo-controlled evaluation of 6 weeks of oral valganciclovir treatment or 6 ...

Phase

2.93 miles

Learn More »

Long-Term Safety and Efficacy Study of BMS-986165 in Participants With Systemic Lupus Erythematosus

The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE)

Phase

2.93 miles

Learn More »

A Study to Assess the Safety Tolerability Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis

Phase

3.23 miles

Learn More »

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed Recurrent or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

PRIMARY OBJECTIVES: I. To confirm tolerability of the combination regimen of inotuzumab ozogamicin followed by blinatumomab. II. To estimate the 1-year event-free survival of older, transplant-ineligible patients with newly diagnosed, Philadelphia (Ph)-negative, CD22-positive, B-cell acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin induction followed by blinatumomab consolidation. (Cohort 1) III. ...

Phase

3.23 miles

Learn More »

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

Levosimendan and its prolonged active metabolite, OR-1896, have been shown to have favorable hemodynamic effects in subjects with pulmonary hypertension and right heart failure. Clinical studies that have been conducted in subjects with right heart failure and pulmonary hypertension suggest levosimendan may be an effective therapy in treatment of subjects ...

Phase

3.23 miles

Learn More »

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

Daratumumab is a human antibody that targets CD38. It is FDA-approved for the treatment of multiple myeloma, has broad-ranging immunomodulatory effects on nonplasma cells that express CD38, and is able to cross the blood-brain barrier. CD38 expression on CD8+ T-cells is significantly increased in the blood of early AD patients ...

Phase

3.23 miles

Learn More »

JBT-101 in Systemic Lupus Erythematosus (SLE)

The objective of this study is to evaluate the efficacy, safety, and tolerability of JBT-101 (also known as lenabasum) in systemic lupus erythematosus (SLE). One hundred adults with active joint disease and at least moderate pain will be enrolled in this study to evaluate treatment of their systemic lupus erythematosus ...

Phase

3.23 miles

Learn More »

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

This study will enroll PH-HFpEF patients that have completed a controlled levosimendan study. These patients will receive weekly open-label doses of levosimendan and be periodically evaluated for safety and effectiveness in extended use.

Phase

3.23 miles

Learn More »